Company · Montreal, Quebec, Canada
Novartis Pharmaceuticals Canada Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 286
- 158 authorized now
- Natural health products
- 5
- 0 active licences
- Medical device licences
- 2
- 0 active
- Notices of Compliance
- 717
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| AFINITOR | 02339501 | Marketed | |
| AFINITOR | 02339528 | Marketed | |
| AFINITOR | 02369257 | Marketed | |
| AFINITOR DISPERZ | 02425645 | Marketed | |
| AFINITOR DISPERZ | 02425653 | Marketed | |
| AFINITOR DISPERZ | 02425661 | Marketed | |
| AIMOVIG | 02479613 | Marketed | |
| AIMOVIG | 02487306 | Marketed | |
| ALOMIDE | 00893560 | Marketed | |
| ATECTURA BREEZHALER | 02498685 | Marketed | |
| ATECTURA BREEZHALER | 02498693 | Marketed | |
| ATECTURA BREEZHALER | 02498707 | Marketed | |
| AZARGA | 02331624 | Marketed | |
| AZOPT | 02238873 | Marketed | |
| BEOVU | 02496976 | Marketed | |
| CILOXAN | 01945270 | Marketed | |
| CILOXAN | 02200864 | Marketed | |
| CIPRODEX | 02252716 | Marketed | |
| COSENTYX | 02438070 | Marketed | |
| COSENTYX | 02525569 | Marketed | |
| COSENTYX | 02529653 | Marketed | |
| COSENTYX | 02529661 | Marketed | |
| COSENTYX | 02547724 | Marketed | |
| DIOVAN | 02270528 | Marketed | |
| DIOVAN | 02289504 | Marketed | |
| DIOVAN 160MG TABLETS | 02244782 | Marketed | |
| DIOVAN 80MG TABLETS | 02244781 | Marketed | |
| DIOVAN-HCT | 02241900 | Marketed | |
| DIOVAN-HCT | 02241901 | Marketed | |
| DIOVAN-HCT | 02246955 | Marketed | |
| DIOVAN-HCT | 02308908 | Marketed | |
| DIOVAN-HCT | 02308916 | Marketed | |
| DUOTRAV PQ | 02278251 | Marketed | |
| DUREZOL | 02415534 | Marketed | |
| ENERZAIR BREEZHALER | 02501244 | Marketed | |
| ENTRESTO | 02446928 | Marketed | |
| ENTRESTO | 02446936 | Marketed | |
| ENTRESTO | 02446944 | Marketed | |
| EXJADE | 02287420 | Marketed | |
| EXJADE | 02287439 | Marketed | |
| EXJADE | 02287447 | Marketed | |
| FABHALTA | 02554313 | Marketed | |
| FEMARA | 02231384 | Marketed | |
| GILENYA | 02365480 | Marketed | |
| GILENYA | 02482533 | Marketed | |
| GLEEVEC | 02253275 | Marketed | |
| GLEEVEC | 02253283 | Marketed | |
| ILARIS | 02460351 | Marketed | |
| ILEVRO | 02411393 | Marketed | |
| ISOPTO CARPINE | 00000868 | Marketed | |
| IZBA | 02457997 | Marketed | |
| JADENU | 02452219 | Marketed | |
| JADENU | 02452227 | Marketed | |
| JADENU | 02452235 | Marketed | |
| JAKAVI | 02388006 | Marketed | |
| JAKAVI | 02388014 | Marketed | |
| JAKAVI | 02388022 | Marketed | |
| JAKAVI | 02434814 | Marketed | |
| KESIMPTA | 02511355 | Marketed | |
| KISQALI | 02473569 | Marketed | |
| KYMRIAH | 02480514 | Marketed | |
| LAMISIL | 02031094 | Marketed | |
| LAMISIL | 02238703 | Marketed | |
| LEQVIO | 02518376 | Marketed | |
| LOCAMETZ | 02537117 | Marketed | |
| LUCENTIS | 02296810 | Marketed | |
| LUCENTIS | 02425629 | Marketed | |
| LUTATHERA | 02484552 | Marketed | |
| LUXTURNA | 02505851 | Marketed | |
| MAXIDEX | 00042560 | Marketed | |
| MAXIDEX | 00042579 | Marketed | |
| MAXITROL | 00042676 | Marketed | |
| MAXITROL | 00358177 | Marketed | |
| MAYZENT | 02496429 | Marketed | |
| MAYZENT | 02496437 | Marketed | |
| MEKINIST | 02409623 | Marketed | |
| MEKINIST | 02409658 | Marketed | |
| MEKINIST | 02539993 | Marketed | |
| MYFORTIC | 02264560 | Marketed | |
| MYFORTIC | 02264579 | Marketed | |
| NEORAL | 02150670 | Marketed | |
| NEORAL | 02150697 | Marketed | |
| NEORAL | 02150689 | Marketed | |
| NEORAL | 02150662 | Marketed | |
| NEORAL | 02237671 | Marketed | |
| NETSPOT | 02490005 | Marketed | |
| NEVANAC | 02308983 | Marketed | |
| PATADAY | 02362171 | Marketed | |
| PATANOL | 02233143 | Marketed | |
| PAZEO | 02458551 | Marketed | |
| PIQRAY | 02497069 | Marketed | |
| PIQRAY | 02497077 | Marketed | |
| PIQRAY | 02497085 | Marketed | |
| PLUVICTO | 02530198 | Marketed | |
| REVOLADE | 02361825 | Marketed | |
| REVOLADE | 02361833 | Marketed | |
| RYDAPT | 02466236 | Marketed | |
| SANDIMMUNE I.V. | 00593257 | Marketed | |
| SANDOSTATIN | 00839191 | Marketed | |
| SANDOSTATIN LAR | 02239323 | Marketed | |
| SANDOSTATIN LAR | 02239324 | Marketed | |
| SANDOSTATIN LAR | 02239325 | Marketed | |
| SCEMBLIX | 02528320 | Marketed | |
| SCEMBLIX | 02528339 | Marketed | |
| SEEBRI BREEZHALER | 02394936 | Marketed | |
| SIMBRINZA | 02435411 | Marketed | |
| SIMULECT | 02242815 | Marketed | |
| TABRECTA | 02527391 | Marketed | |
| TABRECTA | 02527405 | Marketed | |
| TAFINLAR | 02409607 | Marketed | |
| TAFINLAR | 02409615 | Marketed | |
| TAFINLAR | 02540053 | Marketed | |
| TASIGNA | 02315874 | Marketed | |
| TASIGNA | 02368250 | Marketed | |
| TEGRETOL | 00010405 | Marketed | |
| TEGRETOL CR | 00773611 | Marketed | |
| TEGRETOL CR | 00755583 | Marketed | |
| TEGRETOL SUSPENSION | 02194333 | Marketed | |
| TOBRADEX | 00778915 | Marketed | |
| TOBRADEX | 00778907 | Marketed | |
| TOBREX | 00513962 | Marketed | |
| TOBREX | 00614254 | Marketed | |
| TRAVATAN Z | 02318008 | Marketed | |
| TRIESENCE | 02368676 | Marketed | |
| TRILEPTAL 300 MG | 02242068 | Marketed | |
| TRILEPTAL 600 MG | 02242069 | Marketed | |
| TRILEPTAL ORAL SUSPENSION | 02244673 | Marketed | |
| TYKERB | 02326442 | Marketed | |
| ULTIBRO BREEZHALER | 02418282 | Marketed | |
| VIGAMOX | 02252260 | Marketed | |
| VOLTAREN | 00632724 | Marketed | |
| VOLTAREN RAPIDE | 00881635 | Marketed | |
| VOTRIENT | 02352303 | Marketed | |
| XOLAIR | 02260565 | Marketed | |
| XOLAIR | 02459787 | Marketed | |
| XOLAIR | 02459795 | Marketed | |
| XOLAIR | 02545136 | Marketed | |
| XOLAIR | 02545144 | Marketed | |
| XOLAIR | 02545160 | Marketed | |
| ZOLGENSMA | 02509695 | Marketed | |
| ZOMETA CONCENTRATE | 02248296 | Marketed | |
| ZYKADIA | 02436779 | Marketed | |
| AIMOVIG | 02479605 | Approved | |
| AIMOVIG | 02487292 | Approved | |
| BEOVU | 02496984 | Approved | |
| CERTICAN | 02375907 | Approved | |
| CERTICAN | 02375915 | Approved | |
| CERTICAN | 02375923 | Approved | |
| COSENTYX | 02438062 | Approved | |
| KESIMPTA | 02511363 | Approved | |
| LAMISIL DERMGEL | 02239876 | Approved | |
| MAYZENT | 02543370 | Approved | |
| MIACALCIN INJECTION 200IU/ML | 02144301 | Approved | |
| PIQRAY | 02497042 | Approved | |
| RHAPSIDO | 02570076 | Approved | |
| VANRAFIA | 02569590 | Approved | |
| XOLAIR | 02545152 | Approved | |
| ZADITEN - DPS 1MG/ML | 02172585 | Approved | |
| AFINITOR | 02450267 | Cancelled Post Market | |
| ANTURAN 100MG | 00010510 | Cancelled Post Market | |
| ANTURAN 200MG | 00010529 | Cancelled Post Market | |
| AREDIA | 02059770 | Cancelled Post Market | |
| AREDIA 30MG | 02059762 | Cancelled Post Market | |
| AREDIA 90MG | 02059789 | Cancelled Post Market | |
| ARZERRA | 02381559 | Cancelled Post Market | |
| ARZERRA | 02381567 | Cancelled Post Market | |
| BETOPTIC S | 01908448 | Cancelled Post Market | |
| CAFERGOT PB SUP | 00176214 | Cancelled Post Market | |
| CAFERGOT PB TAB | 00176222 | Cancelled Post Market | |
| CAFERGOT SUP | 00782920 | Cancelled Post Market | |
| CAFERGOT TAB | 00176095 | Cancelled Post Market | |
| CYTADREN TAB 250MG | 00587729 | Cancelled Post Market | |
| DESFERAL 2G | 01981250 | Cancelled Post Market | |
| DIOVAN 160MG | 02236809 | Cancelled Post Market | |
| DIOVAN 80MG | 02236808 | Cancelled Post Market | |
| ESTALIS SEQUI | 02243529 | Cancelled Post Market | |
| ESTALIS SEQUI | 02243530 | Cancelled Post Market | |
| ESTRACOMB | 02108186 | Cancelled Post Market | |
| ESTRADERM-100 | 00756792 | Cancelled Post Market | |
| ESTRADERM-25 | 00756849 | Cancelled Post Market | |
| ESTRADERM-50 | 00756857 | Cancelled Post Market | |
| EXTAVIA | 02337819 | Cancelled Post Market | |
| FIORINAL TAB | 00275328 | Cancelled Post Market | |
| FLAREX | 00756784 | Cancelled Post Market | |
| FORADIL DRY POWDER CAPSULES FOR INHALATION | 02230898 | Cancelled Post Market | |
| GLEEVEC | 02244725 | Cancelled Post Market | |
| HYCAMTIN | 02231116 | Cancelled Post Market | |
| HYGROTON 50MG | 00010413 | Cancelled Post Market | |
| ILARIS | 02344939 | Cancelled Post Market | |
| ISOPTO CARPINE | 00000884 | Cancelled Post Market | |
| ISOPTO CARPINE | 00000841 | Cancelled Post Market | |
| LAMISIL | 02031116 | Cancelled Post Market | |
| LENTARON | 02128209 | Cancelled Post Market | |
| LESCOL 20MG | 02061562 | Cancelled Post Market | |
| LESCOL 40MG | 02061570 | Cancelled Post Market | |
| LESCOL XL | 02250527 | Cancelled Post Market | |
| LIORESAL D.S. TAB 20MG | 00636576 | Cancelled Post Market | |
| LIORESAL INTRATHECAL 0.05MG/ML | 02131048 | Cancelled Post Market | |
| LIORESAL INTRATHECAL 0.5MG/ML | 02131056 | Cancelled Post Market | |
| LIORESAL INTRATHECAL 2MG/ML | 02131064 | Cancelled Post Market | |
| LIORESAL TAB 10MG | 00455881 | Cancelled Post Market | |
| LIVOSTIN EYE DROPS | 02131625 | Cancelled Post Market | |
| LOCACORTEN .03% | 00005134 | Cancelled Post Market | |
| LOCACORTEN VIOFORM | 00074470 | Cancelled Post Market | |
| LOCASALEN | 00260568 | Cancelled Post Market | |
| LOPRESOR 100MG | 00397431 | Cancelled Post Market | |
| LOPRESOR 50MG | 00397423 | Cancelled Post Market | |
| LOPRESOR INJ 1.0MG/ML | 00590819 | Cancelled Post Market | |
| LOPRESOR SR 100MG | 00658855 | Cancelled Post Market | |
| LOPRESOR SR 200 MG | 00534560 | Cancelled Post Market | |
| LOTENSIN 10MG | 00885843 | Cancelled Post Market | |
| LOTENSIN 20MG | 00885851 | Cancelled Post Market | |
| LOTENSIN 5MG | 00885835 | Cancelled Post Market | |
| LUDIOMIL TAB 10MG | 00641855 | Cancelled Post Market | |
| LUDIOMIL TAB 25MG | 00360481 | Cancelled Post Market | |
| LUDIOMIL TAB 50MG | 00360503 | Cancelled Post Market | |
| LUDIOMIL TAB 75MG | 00360511 | Cancelled Post Market | |
| MEKINIST | 02409631 | Cancelled Pre Market | |
| MELLARIL | 00027375 | Cancelled Post Market | |
| MELLARIL | 00027359 | Cancelled Post Market | |
| METANDREN 10MG | 00005622 | Cancelled Post Market | |
| METANDREN 25MG | 00005630 | Cancelled Post Market | |
| MIACALCIN NASAL SPRAY 200 IU | 02240775 | Cancelled Post Market | |
| ONBREZ BREEZHALER | 02376938 | Cancelled Post Market | |
| PARLODEL CAP 5MG | 00568643 | Cancelled Post Market | |
| PARLODEL TAB 2.5MG | 00371033 | Cancelled Post Market | |
| PERTOFRANE 25MG | 00010448 | Cancelled Post Market | |
| POTASSIUM-NOVARTIS | 00027596 | Cancelled Post Market | |
| REVOLADE | 02423049 | Cancelled Pre Market | |
| REVOLADE | 02461382 | Cancelled Pre Market | |
| RITALIN 10MG | 00005606 | Cancelled Post Market | |
| RITALIN 20MG | 00005614 | Cancelled Post Market | |
| RITALIN-SR TAB 20MG | 00632775 | Cancelled Post Market | |
| ROGITINE 5MG/VIAL | 00005193 | Cancelled Post Market | |
| SANDOSTATIN | 00839205 | Cancelled Post Market | |
| SANDOSTATIN | 00839213 | Cancelled Post Market | |
| SANDOSTATIN | 02049392 | Cancelled Post Market | |
| SANSERT | 00027499 | Cancelled Post Market | |
| SEBIVO | 02288389 | Cancelled Post Market | |
| SER-AP-ES TAB | 00074608 | Cancelled Post Market | |
| SERENTIL TAB 10MG | 00027448 | Cancelled Post Market | |
| SERENTIL TAB 25MG | 00027456 | Cancelled Post Market | |
| SERENTIL TAB 50MG | 00027464 | Cancelled Post Market | |
| SERPASIL 0.25MG | 00005665 | Cancelled Post Market | |
| SLOW K | 00074225 | Cancelled Post Market | |
| SLOW TRASICOR TAB 160MG | 00534587 | Cancelled Post Market | |
| SLOW TRASICOR TAB 80MG | 00534579 | Cancelled Post Market | |
| STARLIX 120MG | 02245439 | Cancelled Post Market | |
| STARLIX 180MG | 02245440 | Cancelled Post Market | |
| STARLIX 60MG | 02245438 | Cancelled Post Market | |
| TASIGNA | 02481715 | Cancelled Post Market | |
| TEGRETOL CHEWTABS 100 MG | 00369810 | Cancelled Post Market | |
| TEGRETOL CHEWTABS 200 MG | 00665088 | Cancelled Post Market | |
| TOBREXAN | 02261243 | Cancelled Pre Market | |
| TOFRANIL 10MG | 00010464 | Cancelled Post Market | |
| TOFRANIL 25MG | 00010472 | Cancelled Post Market | |
| TOFRANIL 50MG | 00010480 | Cancelled Post Market | |
| TOFRANIL 75MG | 00306487 | Cancelled Post Market | |
| TRANSDERM-NITRO 0.2 | 00584223 | Cancelled Post Market | |
| TRANSDERM-NITRO 0.4 | 00852384 | Cancelled Post Market | |
| TRANSDERM-NITRO 0.6 | 02046156 | Cancelled Post Market | |
| TRANSDERM-NITRO 0.8 | 02046164 | Cancelled Post Market | |
| TRASICOR TAB 20MG | 00402567 | Cancelled Post Market | |
| TRASICOR TAB 40MG | 00402575 | Cancelled Post Market | |
| TRASICOR TAB 80MG | 00402583 | Cancelled Post Market | |
| TRILEPTAL 150 MG | 02242067 | Cancelled Post Market | |
| VIOFORM 3% | 00005142 | Cancelled Post Market | |
| VIOFORM 3% | 00005797 | Cancelled Post Market | |
| VIOFORM HYDROCORTISONE MILD | 00074489 | Cancelled Post Market | |
| VIVELLE 100MCG | 02204444 | Cancelled Post Market | |
| VIVELLE 37.5MCG | 02204401 | Cancelled Post Market | |
| VIVELLE 50MCG | 02204428 | Cancelled Post Market | |
| VIVELLE 75MCG | 02204436 | Cancelled Post Market | |
| VOLTAREN | 00514012 | Cancelled Post Market | |
| VOLTAREN | 00632732 | Cancelled Post Market | |
| VOLTAREN OPHTHA | 01940414 | Cancelled Post Market | |
| VOLTAREN SR | 00590827 | Cancelled Post Market | |
| VOLTAREN SR | 00782459 | Cancelled Post Market | |
| VOLTAREN TAB 25MG | 00514004 | Cancelled Post Market | |
| VOTRIENT | 02352311 | Cancelled Pre Market | |
| ZADITOR | 02279223 | Cancelled Post Market | |
| ZOFRAN | 02213567 | Cancelled Post Market | |
| ZOFRAN | 02213575 | Cancelled Post Market | |
| ZOFRAN | 02213745 | Cancelled Post Market | |
| ZOFRAN | 02229639 | Cancelled Post Market | |
| ZOMETA LYOPHILIZED POWDER | 02242725 | Cancelled Post Market |
Natural health products
Active licences first, newest first.
| Name | NPN | Status | Licensed |
|---|---|---|---|
| Slow-K | 80040226 | Discontinued | |
| Phosphate Novartis | 80027202 | Discontinued | |
| Vitalux-S | 02247216 | Discontinued | |
| Vitalux | 02245911 | Discontinued | |
| Timed Release Vitalux | 02240199 | Discontinued |
Medical device licences
Active licences first, newest first.
| Name | Licence | Status | First licensed |
|---|---|---|---|
| PATIENT TREATMENT KIT FOR USE WITH VISUDYNE | 21384 | Discontinued at renewal · Class 2 | |
| APLIGRAF (BI-LAYERED HUMAN SKIN EQUIVALENT) | 1154 | Cancelled · Class 4 |
Notices of Compliance
Newest first.
- XOLAIROctober 9, 2026 · NOC 38445 · Supplement to a New Drug Submission (SNDS)
- VIGAMOXOctober 9, 2026 · NOC 38449 · Supplement to a New Drug Submission (SNDS)
- KISQALISeptember 17, 2026 · NOC 38309 · Supplement to a New Drug Submission (SNDS)
- GILENYASeptember 2, 2026 · NOC 38223 · Supplement to a New Drug Submission (SNDS)
- PLUVICTOSeptember 2, 2026 · NOC 38230 · Supplement to a New Drug Submission (SNDS)
- MAYZENTSeptember 1, 2026 · NOC 38224 · Supplement to a New Drug Submission (SNDS)
- LEQVIOAugust 27, 2026 · NOC 38203 · Supplement to a New Drug Submission (SNDS)
- CERTICANAugust 14, 2026 · NOC 38121 · Supplement to a New Drug Submission (SNDS)
- FABHALTAAugust 14, 2026 · NOC 38123 · Supplement to a New Drug Submission (SNDS)
- KESIMPTAAugust 4, 2026 · NOC 38037 · Supplement to a New Drug Submission (SNDS)
- TEGRETOL; TEGRETOL CR; TEGRETOL SUSPENSIONJuly 31, 2026 · NOC 38045 · Supplement to a New Drug Submission (SNDS)
- NEORAL; SANDIMMUNE I.V.July 30, 2026 · NOC 38021 · Supplement to a New Drug Submission (SNDS)
- ENTRESTOJuly 30, 2026 · NOC 38024 · Supplement to a New Drug Submission (SNDS)
- AZARGAJuly 29, 2026 · NOC 38005 · Supplement to a New Drug Submission (SNDS)
- JAKAVIJuly 23, 2026 · NOC 37975 · Supplement to a New Drug Submission (SNDS)
- RHAPSIDOJuly 16, 2026 · NOC 37930 · New Drug Submission (NDS)
- VANRAFIAJuly 2, 2026 · NOC 37820 · New Drug Submission (NDS)
- TASIGNAJune 26, 2026 · NOC 37785 · Supplement to a New Drug Submission (SNDS)
- COSENTYXJune 12, 2026 · NOC 37698 · Supplement to a New Drug Submission (SNDS)
- COSENTYXMay 29, 2026 · NOC 37627 · Supplement to a New Drug Submission (SNDS)
- KISQALIMay 7, 2026 · NOC 37499 · Supplement to a New Drug Submission (SNDS)
- FABHALTAApril 30, 2026 · NOC 37443 · Supplement to a New Drug Submission (SNDS)
- VOLTARENApril 29, 2026 · NOC 37437 · Supplement to a New Drug Submission (SNDS)
- VOLTAREN RAPIDEApril 29, 2026 · NOC 37438 · Supplement to a New Drug Submission (SNDS)
- TABRECTAApril 9, 2026 · NOC 37309 · Supplement to a New Drug Submission (SNDS)
- KISQALIApril 7, 2026 · NOC 37270 · Supplement to a New Drug Submission (SNDS)
- KISQALIMarch 12, 2026 · NOC 37093 · Supplement to a New Drug Submission (SNDS)
- ENTRESTOFebruary 26, 2026 · NOC 37001 · Supplement to a New Drug Submission (SNDS)
- TAFINLARFebruary 16, 2026 · NOC 36914 · Supplement to a New Drug Submission (SNDS)
- MEKINISTFebruary 16, 2026 · NOC 36915 · Supplement to a New Drug Submission (SNDS)
- SANDOSTATIN; SANDOSTATIN LARFebruary 16, 2026 · NOC 36916 · Supplement to a New Drug Submission (SNDS)
- LUXTURNAFebruary 13, 2026 · NOC 36940 · Supplement to a New Drug Submission (SNDS)
- SCEMBLIXJanuary 27, 2026 · NOC 36793 · Supplement to a New Drug Submission (SNDS)
- GLEEVECJanuary 15, 2026 · NOC 36734 · Supplement to a New Drug Submission (SNDS)
- MYFORTICJanuary 8, 2026 · NOC 36695 · Supplement to a New Drug Submission (SNDS)
- ZYKADIADecember 10, 2025 · NOC 36516 · Supplement to a New Drug Submission (SNDS)
- GILENYADecember 2, 2025 · NOC 36468 · Supplement to a New Drug Submission (SNDS)
- MEKINISTNovember 25, 2025 · NOC 36426 · Supplement to a New Drug Submission (SNDS)
- ZOLGENSMANovember 21, 2025 · NOC 36462 · Supplement to a New Drug Submission (SNDS)
- NEORALNovember 14, 2025 · NOC 36383 · Supplement to a New Drug Submission (SNDS)
- KYMRIAHNovember 4, 2025 · NOC 36333 · Supplement to a New Drug Submission (SNDS)
- PIQRAYOctober 24, 2025 · NOC 36257 · Supplement to a New Drug Submission (SNDS)
- KESIMPTAOctober 14, 2025 · NOC 36157 · Supplement to a New Drug Submission (SNDS)
- DUREZOLOctober 3, 2025 · NOC 36105 · Supplement to a New Drug Submission (SNDS)
- SCEMBLIXOctober 1, 2025 · NOC 36093 · Supplement to a New Drug Submission (SNDS)
- REVOLADEAugust 19, 2025 · NOC 35865 · Supplement to a New Drug Submission (SNDS)
- SCEMBLIXJuly 25, 2025 · NOC 35750 · Supplement to a New Drug Submission (SNDS)
- GLEEVECJuly 16, 2025 · NOC 35678 · Supplement to a New Drug Submission (SNDS)
- COSENTYXJuly 4, 2025 · NOC 35626 · Supplement to a New Drug Submission (SNDS)
- TOBREXJuly 4, 2025 · NOC 35632 · Supplement to a New Drug Submission (SNDS)
- TRILEPTALJuly 2, 2025 · NOC 35607 · Supplement to a New Drug Submission (SNDS)
- COSENTYXJune 24, 2025 · NOC 35576 · Supplement to a New Drug Submission (SNDS)
- ILARISJune 19, 2025 · NOC 35649 · Supplement to a New Drug Submission (SNDS)
- MAYZENTJune 16, 2025 · NOC 35524 · Supplement to a New Drug Submission (SNDS)
- TABRECTAJune 16, 2025 · NOC 35586 · Supplement to a New Drug Submission (SNDS)
- KISQALIJune 12, 2025 · NOC 35510 · Supplement to a New Drug Submission (SNDS)
- MEKINISTJune 11, 2025 · NOC 35499 · Supplement to a New Drug Submission (SNDS)
- TAFINLARJune 10, 2025 · NOC 35503 · Supplement to a New Drug Submission (SNDS)
- NETSPOTJune 3, 2025 · NOC 35467 · Supplement to a New Drug Submission (SNDS)
- LEQVIOMay 15, 2025 · NOC 35347 · Supplement to a New Drug Submission (SNDS)
- SEEBRI BREEZHALERMay 6, 2025 · NOC 35311 · Supplement to a New Drug Submission (SNDS)
- TEGRETOL; TEGRETOL CR; TEGRETOL SUSPENSIONApril 29, 2025 · NOC 35264 · Supplement to a New Drug Submission (SNDS)
- KISQALIApril 20, 2025 · NOC 35215 · Supplement to a New Drug Submission (SNDS)
- GILENYAApril 17, 2025 · NOC 35213 · Supplement to a New Drug Submission (SNDS)
- ZOLGENSMAApril 17, 2025 · NOC 35222 · Supplement to a New Drug Submission (SNDS)
- DUREZOLApril 8, 2025 · NOC 35146 · Supplement to a New Drug Submission (SNDS)
- XOLAIRApril 1, 2025 · NOC 35100 · Supplement to a New Drug Submission (SNDS)
- LUTATHERAMarch 31, 2025 · NOC 35098 · Supplement to a New Drug Submission (SNDS)
- NETSPOTMarch 31, 2025 · NOC 35103 · Supplement to a New Drug Submission (SNDS)
- PLUVICTOMarch 28, 2025 · NOC 35087 · Supplement to a New Drug Submission (SNDS)
- PLUVICTOMarch 19, 2025 · NOC 35046 · Supplement to a New Drug Submission (SNDS)
- TAFINLARMarch 14, 2025 · NOC 35017 · Supplement to a New Drug Submission (SNDS)
- COSENTYXMarch 11, 2025 · NOC 34994 · Supplement to a New Drug Submission (SNDS)
- ZOLGENSMAMarch 7, 2025 · NOC 34986 · Supplement to a New Drug Submission (SNDS)
- PLUVICTOMarch 6, 2025 · NOC 34960 · Supplement to a New Drug Submission (SNDS)
- LUTATHERAMarch 6, 2025 · NOC 34979 · Supplement to a New Drug Submission (SNDS)
- PLUVICTOMarch 3, 2025 · NOC 34988 · Supplement to a New Drug Submission (SNDS)
- TASIGNAFebruary 17, 2025 · NOC 34856 · Supplement to a New Drug Submission (SNDS)
- LEQVIOFebruary 11, 2025 · NOC 34817 · Supplement to a New Drug Submission (SNDS)
- MYFORTICJanuary 29, 2025 · NOC 34766 · Supplement to a New Drug Submission (SNDS)
- FABHALTAJanuary 6, 2025 · NOC 34639 · New Drug Submission (NDS)
- LUTATHERADecember 13, 2024 · NOC 34582 · Supplement to a New Drug Submission (SNDS)
- TAFINLARDecember 5, 2024 · NOC 34501 · Supplement to a New Drug Submission (SNDS)
- MEKINISTDecember 5, 2024 · NOC 34502 · Supplement to a New Drug Submission (SNDS)
- ZOLGENSMADecember 5, 2024 · NOC 34508 · Supplement to a New Drug Submission (SNDS)
- KYMRIAHOctober 29, 2024 · NOC 34322 · Supplement to a New Drug Submission (SNDS)
- TASIGNAOctober 17, 2024 · NOC 34222 · Supplement to a New Drug Submission (SNDS)
- TRILEPTALSeptember 24, 2024 · NOC 34108 · Supplement to a New Drug Submission (SNDS)
- COSENTYXSeptember 17, 2024 · NOC 34148 · Supplement to a New Drug Submission (SNDS)
- LUTATHERASeptember 16, 2024 · NOC 34026 · Supplement to a New Drug Submission (SNDS)
- BEOVUSeptember 13, 2024 · NOC 34023 · Supplement to a New Drug Submission (SNDS)
- COSENTYXAugust 20, 2024 · NOC 33847 · Supplement to a New Drug Submission (SNDS)
- LEQVIOAugust 19, 2024 · NOC 33834 · Supplement to a New Drug Submission (SNDS)
- TRAVATAN ZAugust 14, 2024 · NOC 33816 · Supplement to a New Drug Submission (SNDS)
- PIQRAYAugust 12, 2024 · NOC 33802 · Supplement to a New Drug Submission (SNDS)
- TABRECTAJuly 29, 2024 · NOC 33722 · Supplement to a New Drug Submission (SNDS)
- TASIGNAJuly 17, 2024 · NOC 33663 · Supplement to a New Drug Submission (SNDS)
- SCEMBLIXJuly 12, 2024 · NOC 33629 · Supplement to a New Drug Submission (SNDS)
- KISQALIJuly 5, 2024 · NOC 33591 · Supplement to a New Drug Submission (SNDS)
- XIIDRAJune 28, 2024 · NOC 33533 · Supplement to a New Drug Submission (SNDS)
The latest 100 of 717.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- Locametz powder for solution, kit; Out of specification (unknown impurity)January 12, 2026 · Radiopharmaceuticals · Product quality · Type III
- Votrient: The dissolution is out of specification in the affected lotNovember 16, 2023 · Drugs · Product quality · Type II
- Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancerNovember 1, 2022 · Drugs · Labelling
- Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and MalignancyOctober 31, 2022 · Drugs · New safety information - Product safety
- ZOLGENSMA (onasemnogene abeparvovec) and Fatal Cases of Acute Liver FailureSeptember 12, 2022 · Biologic or vaccine · New safety information
- NETSPOT: Out of SpecificationMarch 24, 2022 · Radiopharmaceuticals · Product quality · Type III
- BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular OcclusionFebruary 3, 2022 · Drugs · New safety information - Product safety
- GILENYA (fingolimod) - Risk of Liver InjuryJanuary 18, 2021 · Drugs · Product safety
- GILENYA (fingolimod) - Risk of Congenital MalformationsDecember 19, 2019 · Drugs · Product safety
- Xolair (2019-09-06)September 6, 2019 · Drugs · Product safety · Type II
- REVOLADE (eltrombopag) - Risk of Severe HepatotoxicityAugust 25, 2016 · Drugs · Product safety
- BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B ReactivationMay 4, 2016 · Drugs · Product safety
- CellCept (mycophenolate mofetil) and MYFORTIC (mycophenolate sodium) - Serious Risk of Teratogenicity in Mycophenolate-Containing ProductsJanuary 18, 2016 · Drugs · Product safety
- ARZERRA (ofatumumab) - Fatal Infusion Reaction Reported in a Patient with Chronic Lymphocytic Leukemia - For Health ProfessionalsAugust 6, 2014 · Biologic or vaccine · Product safety
- ARZERRA (ofatumumab) - Fatal Infusion Reaction Reported in a Patient with Chronic Lymphocytic Leukemia - For the PublicAugust 6, 2014 · Biologic or vaccine · Product safety
- ARZERRA (ofatumumab) - Recommendations to Screen, Monitor and to Manage Hepatitis B Virus Reactivation - For the PublicJanuary 27, 2014 · Biologic or vaccine · Product safety
- ARZERRA (ofatumumab) - Recommendations to Screen, Monitor and to Manage Hepatitis B Virus Reactivation - For Health ProfessionalsJanuary 27, 2014 · Biologic or vaccine · Product safety
- VOTRIENT (pazopanib hydrochloride) - Important Change to Frequency of Liver Test Monitoring - For the PublicAugust 9, 2013 · Drugs · Product safety
- VOTRIENT (pazopanib hydrochloride) - Important Change to Frequency of Liver Test Monitoring - For Health ProfessionalsAugust 9, 2013 · Drugs · Product safety
- TASIGNA (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For Health ProfessionalsApril 12, 2013 · Drugs · Product safety
- TASIGNA (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For the PublicApril 12, 2013 · Drugs · Product safety
- TYKERB (lapatinib ditosylate) - Updated Information on Efficacy - For Health ProfessionalsMarch 25, 2013 · Drugs
- TYKERB (lapatinib ditosylate) - Updated Information on Efficacy - For the PublicMarch 25, 2013 · Drugs
- GILENYA (fingolimod) - Stronger Safety Recommendations Regarding First-Dose Heart Monitoring and Use in Patients with Heart Conditions - For Health ProfessionalsAugust 23, 2012 · Drugs
- GILENYA (fingolimod) - Stronger Safety Recommendations Regarding First-Dose Heart Monitoring and Use in Patients with Heart Conditions - For the PublicAugust 23, 2012 · Drugs
- Gilenya (fingolimod): MS drug under Health Canada review in light of serious adverse eventsFebruary 27, 2012 · Drugs · Product safety
- Gilenya (fingolimod): MS drug under Health Canada review in light of serious adverse eventsJanuary 1, 2012 · Drugs
- Myfortic (mycophenolate sodium) - Reports of Pure Red Cell Aplasia in Patients - For Health ProfessionalsDecember 23, 2009 · Drugs
- Archived - Myfortic (mycophenolate sodium) - Reports of Pure Red Cell Aplasia in Patients - For the PublicDecember 23, 2009 · Drugs
- One Lot of Zaditen Tablets (for Asthma) Recalled Due to Potential Health RisksDecember 4, 2009 · Drugs · Labelling
- Exjade (deferasirox) - Proposed Changes to the Canadian Product Monograph - For Health ProfessionalsDecember 3, 2009 · Drugs
- Archived - Exjade (deferasirox) - Proposed Changes to the Canadian Product Monograph - For the PublicDecember 3, 2009 · Drugs
- Gleevec (imatinib mesylate) - Advisories, Warnings and Recalls for Health ProfessionalsOctober 2, 2006 · Drugs
- Important Safety Information on Foradil (formoterol fumarate) – Novartis Pharmaceuticals Canada Inc. – For Health ProfessionalsSeptember 9, 2005 · Drugs · Product safety
- Association of TRILEPTAL (oxcarbazepine) with Life-Threatening Dermatological Reactions and Multi-Organ Hypersensitivity – Novartis Pharmaceuticals Canada Inc. – For Health ProfessionalsApril 27, 2005 · Drugs · New safety information
- Archived - Important Drug Warning - Lamisil - (terbinafine HCL) - NovartisMay 17, 2001 · Drugs